Dimethyl fumarate
- Generic Name
- Dimethyl fumarate
- Brand Names
- Tecfidera, Skilarence, Dimethyl fumarate Neuraxpharm, Dimethyl fumarate Mylan, Dimethyl fumarate Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C6H8O4
- CAS Number
- 624-49-7
- Unique Ingredient Identifier
- FO2303MNI2
- Background
Dimethyl fumarate is an agent indicated for the treatment of relapsing forms of multiple sclerosis. The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MMF up-regulates the Nuclear factor (erythroid-derived 2)-...
- Indication
Dimethyl fumarate is indicated for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
- Associated Conditions
- Clinically Isolated Syndrome (CIS), Relapsing Forms of MS, Relapsing Remitting Multiple Sclerosis (RRMS), Active Secondary Progressive Multiple Sclerosis (SPMS)
- Associated Therapies
- -
Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera
- Conditions
- Interventions
- First Posted Date
- 2015-04-07
- Last Posted Date
- 2020-03-31
- Lead Sponsor
- Biogen
- Target Recruit Count
- 102
- Registration Number
- NCT02410278
- Locations
- 🇺🇸
Research Site, Madison, Wisconsin, United States
Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS
- Conditions
- Interventions
- First Posted Date
- 2015-04-07
- Last Posted Date
- 2017-10-23
- Lead Sponsor
- Biogen
- Target Recruit Count
- 22
- Registration Number
- NCT02410200
- Locations
- 🇹🇷
Research Site, Ankara, Turkey
Study to Evaluate Whether a Medication Event Monitoring System (MEMS) Can Improve Adherence to Tecfidera Treatment in Multiple Sclerosis Patients.
- Conditions
- Interventions
- First Posted Date
- 2015-01-21
- Last Posted Date
- 2017-05-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 84
- Registration Number
- NCT02343159
- Locations
- 🇺🇸
Research Site, Winchester, Virginia, United States
Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
- Conditions
- Interventions
- First Posted Date
- 2015-01-13
- Last Posted Date
- 2019-06-28
- Lead Sponsor
- Virginia Commonwealth University
- Target Recruit Count
- 12
- Registration Number
- NCT02337426
- Locations
- 🇺🇸
Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States
Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve)
- Conditions
- Interventions
- First Posted Date
- 2014-12-23
- Last Posted Date
- 2016-04-08
- Lead Sponsor
- Biogen
- Target Recruit Count
- 24
- Registration Number
- NCT02323269
- Locations
- 🇨🇦
Research Site, Montreal, Quebec, Canada
Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)
- Conditions
- Interventions
- First Posted Date
- 2014-11-05
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 156
- Registration Number
- NCT02283853
- Locations
- 🇧🇬
MHATNP 'Sv.Naum', EAD, Sofia, Bulgaria
🇮🇱Chaim Sheba Medical Center, Ramat Gan, Israel
🇫🇷Hopital Roger Salengro - CHU Lille, Lille Cedex, Nord, France
Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)
- Conditions
- First Posted Date
- 2014-06-10
- Last Posted Date
- 2016-06-07
- Lead Sponsor
- Biogen
- Target Recruit Count
- 530
- Registration Number
- NCT02159573
- Locations
- 🇺🇸
Research Site, Milwaukee, Wisconsin, United States
Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany
- Conditions
- Interventions
- First Posted Date
- 2014-04-29
- Last Posted Date
- 2017-04-18
- Lead Sponsor
- Biogen
- Target Recruit Count
- 214
- Registration Number
- NCT02125604
- Locations
- 🇩🇪
Research Site, Siegen, Germany
Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.
- Conditions
- Interventions
- First Posted Date
- 2014-03-27
- Last Posted Date
- 2017-06-02
- Lead Sponsor
- Biogen
- Target Recruit Count
- 71
- Registration Number
- NCT02097849
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2014-03-18
- Last Posted Date
- 2016-12-28
- Lead Sponsor
- Biogen
- Target Recruit Count
- 241
- Registration Number
- NCT02090413
- Locations
- 🇬🇧
Research Site, Swansea, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.